Replies to post #107031 on Biotech Values

[jq1234]

I'd say M118 partnership is more urgent than FoB deal. Biosimilar pathway is still to be worked out. MNTA probably can fund FoB on its own for awhile.

[mcbio]

Re: MNTA/M118

I think an M118 partnership will likely come before an FoB partnership, but I don’t have a strong opinion on this.

I wonder, at what point, assuming no Teva generic Lovenox for the foreseeable future and no M118 partner, would MNTA consider running an additional trial for M118 on its own dime to potentially enhance M118's partnering prospects? At some point, as the sole generic Lovenox, they're likely going to have the cash to run such a trial I would assume. My biggest question is: has MNTA done essentially all they effectively can to enhance M118's partnering prospects or would an additional trial help on this front if the cash is there?